Results 151 to 160 of about 1,221,694 (269)

Circular RNA CCT3 is a unique molecular marker in bladder cancer. [PDF]

open access: yesBMC Cancer, 2023
Luo L   +6 more
europepmc   +1 more source

Canadian Sarcoma GroupWorkshopSarcomas: Molecular Markers to Therapeutics,26–27 February 2000,Toronto, Canada [PDF]

open access: hybrid, 2000
Vivien Bramwell   +26 more
openalex   +1 more source

Genetic divergence between sub-accessions of the melon using molecular markers

open access: gold, 2022
Clisneide Coelho de Amorim   +4 more
openalex   +1 more source

Detection of circulating tumor DNA in colorectal cancer patients using a methylation‐specific droplet digital PCR multiplex

open access: yesMolecular Oncology, EarlyView.
We developed a cost‐effective methylation‐specific droplet digital PCR multiplex assay containing tissue‐conserved and tumor‐specific methylation markers. The assay can detect circulating tumor DNA with high accuracy in patients with localized and metastatic colorectal cancer.
Luisa Matos do Canto   +8 more
wiley   +1 more source

Transcriptional network analysis of PTEN‐protein‐deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication

open access: yesMolecular Oncology, EarlyView.
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice   +16 more
wiley   +1 more source

Next‐generation proteomics improves lung cancer risk prediction

open access: yesMolecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy